Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Increased Reports of Intraocular Inflammation due to Eylea Injections

March 5, 2018 By Law Offices of Thomas J. Lamb, P.A.


About Eylea

Eylea is an eye injection that is indicated for the treatment of the following diseases of the retina:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR) in Patients with DME

Regeneron Pharmaceuticals is responsible for manufacturing Eylea, which was approved by the FDA in 2011.  

Increase in Side Effects

Over the past several months, an increased number of patients who receive Eylea injections have experienced sharp declines in vision, pain, and even vision loss.  These symptoms were attributed to intraocular inflammation (IOI), which is a known side effect of Eylea and similar drugs. According to a Bloomberg article from February 21, 2018, the “FDA received 71 reports last year” out of the 2.2 million vials of Eylea that were distributed, which was “almost triple 2014 when [one million vials were distributed and] the next-highest number were made.” While the total number of reported incidents remains low, the American Society of Retina Specialists (ASRS) felt that the situation warranted a letter to its members.  They maintained that the benefits of Eylea far outweigh the reported risks, but that doctors should still be aware of the unexplained increased potential for the IOI side effect. The manufacturer launched an internal investigation to ascertain the cause of this spike in adverse events in late February.  

Assumed Cause

Regeneron released the following information in a February 28, 2018 letter they sent to healthcare providers:

We did not identify any association of IOI rates with the Eylea drug itself, but an association was seen with certain batches of the syringe included in specific lots of final packaged Eylea kits.

While Regeneron was quick to point the finger at the manufacturer of the syringes included in their Eylea kits–Becton, Dickinson & Company–no specific flaw or contamination of the syringes was discussed. They did however provide eight lot numbers of Eylea kits that contained “affected syringes,” and advised doctors not to use the syringes provided in those lots. Lastly, they stated that they will provide a more detailed report of their findings in an “upcoming scientific meeting.” We will continue to monitor the medical news concerning Eylea and the spike in incidences of IOI, and report on significant developments as we become aware of them.    

 

Written by: Heather Helmendach, Legal Assistant 
Law Offices of Thomas J. Lamb, P.A.  

 

Drug Injury Watch: Side Effects News & Reports
Drug Injury Law: Medical & Legal Information

Filed Under: Unsafe Drugs Tagged With: AMD, American Society of Retina Specialists, ASRS, Diabetic Macular Edema, Diabetic Retinopathy, DME, DR, eylea, eylea investigation, eylea side effects, intraocular inflammation, IOI, Macular Edema Following Retinal Vein Occlusion, Neovascular Age-Related Macular Degeneration, regeneron pharmaceuticals, RVO

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.